Ebola treatment breakthrough highlights Wall Street’s obsession with profit and indifference to saving lives
Barron’s reports: Monday brought a spot of good news in a bleak summer: Scientists testing Ebola drugs in the Democratic Republic of Congo found some that seemed to work. Wall Street shrugged. Scientists cut short a trial of four experimental Ebola drugs after two of them, including one developed by Regeneron Pharmaceuticals (ticker: REGN), showed extremely promising results. Ninety percent of patients who took the drugs soon after infection survived. Overall, 29% of Ebola patients dosed with Regeneron’s drug died,…